Enovis Corporation

Yeah, so I think we've talked about foot and ankle passing through $100 million this year. There wasn't any Lima foot and ankle business of any consequence that came in, but we did bring NovaStep in last year, which really helped to position us to bust through that $100 million ramp. Look, our foot and ankle business for a number of quarters now has been growing very strongly and comfortably above market levels. um you know based on the the work we did to put that channel together and the hard work of putting the channel together that we did and now having that strong aligned channel and then just a ton of great innovation that we've been pumping into that business i know and then that's in the u.s we're also growing double digits outside the u.s in in that business um you know i i think that uh you know i commented on the the markets uh more broadly uh you know earlier and i think you know i think that would apply to foot and ankle as well that you know we probably have uh not as good a market situation this year as we did last year, but I think our teams are doing a great job of executing share gain in that environment and have done it for a number of quarters now, and we're really pleased with the engine that we built there. Thank you.

And the next question comes from Young Lee with Jefferies. Please go ahead.

All right, great. Thanks so much for taking the question. I'll just keep it to one. Maybe just to follow up on the U.S. extremities business a little bit more, you know, appreciate the comments on the foot and ankle side. But on the U.S. shoulder side, I guess I'm curious, when do you expect that to return to, you know, one and a half to two times market growth? And then your thoughts on the sustainability of that in light of some of the new robotic competitors coming to the markets?